Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 172
Filter
1.
Proc Biol Sci ; 287(1931): 20200922, 2020 07 29.
Article in English | MEDLINE | ID: mdl-33043867

ABSTRACT

Most of the world's crops depend on pollinators, so declines in both managed and wild bees raise concerns about food security. However, the degree to which insect pollination is actually limiting current crop production is poorly understood, as is the role of wild species (as opposed to managed honeybees) in pollinating crops, particularly in intensive production areas. We established a nationwide study to assess the extent of pollinator limitation in seven crops at 131 locations situated across major crop-producing areas of the USA. We found that five out of seven crops showed evidence of pollinator limitation. Wild bees and honeybees provided comparable amounts of pollination for most crops, even in agriculturally intensive regions. We estimated the nationwide annual production value of wild pollinators to the seven crops we studied at over $1.5 billion; the value of wild bee pollination of all pollinator-dependent crops would be much greater. Our findings show that pollinator declines could translate directly into decreased yields or production for most of the crops studied, and that wild species contribute substantially to pollination of most study crops in major crop-producing regions.


Subject(s)
Agriculture , Crops, Agricultural , Pollination , Animals , Bees , Food Supply , United States
2.
Ann Oncol ; 31(2): 246-256, 2020 02.
Article in English | MEDLINE | ID: mdl-31959341

ABSTRACT

BACKGROUND: The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of improving disease-free survival (DFS) with the addition of bevacizumab to oxaliplatin-based chemotherapy in stage III colon cancer (CC). We report here the long-term survival results (S-AVANT). PATIENTS AND METHODS: Patients with curatively resected stage III CC were randomly assigned to FOLFOX4, FOLFOX4-bevacizumab, or XELOX-bevacizumab. RESULTS: A total of 2867 patients were randomized: FOLFOX4: n = 955, FOLFOX4-bevacizumab: n = 960, XELOX-bevacizumab: n = 952. With a median of 6.73 years follow-up (interquartile range 5.51-10.54), 672 patients died, of whom 198 (20.7%), 250 (26.0%), and 224 (23.5%) were in the FOLFOX4, FOLFOX4-bevacizumab, and XELOX-bevacizumab arms, respectively. The 10-year overall survival (OS) rates were 74.6%, 67.2%, and 69.9%, (P = 0.003) and 5-year disease-free survival (DFS) rates were 73.2%, 68.5%, and 71.0% (P = 0.174), respectively. OS and DFS hazard ratios were 1.29 [95% confidence interval (CI) 1.07-1.55; P = 0.008] and 1.16 (95% CI 0.99-1.37; P = 0.063) for FOLFOX4-bevacizumab versus FOLFOX4 and 1.15 (95% CI 0.95-1.39; P = 0.147) and 1.1 (95% CI 0.93-1.29; P = 0.269) for XELOX-bevacizumab versus FOLFOX4, respectively. CC-related deaths (n = 542) occurred in 157 (79.3%) patients receiving FOLFOX4, 205 (82.0%) receiving FOLFOX4-bevacizumab, and 180 (80.4%) receiving XELOX-bevacizumab (P = 0.764), while non-CC-related deaths occurred in 41 (20.7%), 45 (18.0%), and 44 (19.6%) patients, respectively. Cardiovascular-related and sudden deaths during treatment or follow-up were reported in 13 (6.6%), 17 (6.8%), and 14 (6.3%) patients, in the FOLFOX4, FOLFOX4-bevacizuamb, and XELOX-bevacizumab arms, respectively (P = 0.789). Treatment arm, sex, age, histological differentiation, performance status, T/ N stages, and localization of primary tumor were independent prognostic factors of OS in stage III. CONCLUSIONS: S-AVANT confirms the initial AVANT report. No benefit of the bevacizumab addition to FOLFOX4 adjuvant therapy in patients with stage III CC was observed in terms of DFS with a negative effect in OS, without increase in non-CC related deaths. CLINICAL TRIAL IDENTIFICATION: NCT00112918.


Subject(s)
Colonic Neoplasms , Organoplatinum Compounds , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bevacizumab/adverse effects , Chemotherapy, Adjuvant , Colonic Neoplasms/drug therapy , Colonic Neoplasms/pathology , Disease-Free Survival , Fluorouracil/adverse effects , Humans , Leucovorin/adverse effects , Neoplasm Staging , Organoplatinum Compounds/adverse effects
3.
Ecology ; 100(6): e02697, 2019 06.
Article in English | MEDLINE | ID: mdl-31012965

ABSTRACT

Many species of bumble bee (Bombus) have declined in range and abundance across Europe, the Americas, and Asia, whereas other species have persisted and remain common and widespread. One explanation as to why some species have declined, based primarily on studies of the European bumble bee fauna, is that declining species have relatively narrow pollen-foraging niches and are less able to use alternative host plants in the absence of their preferred hosts. Though extensively explored in Europe, this hypothesis has not been investigated in North America, in part due to incomplete information on the foraging niche of many species. We selected 12 bumble bee species found in Michigan and quantified their pollen diets using museum specimens. We also extensively resurveyed the state to understand their contemporary status and distribution. Compared to a pre-2000 baseline, six species remain relatively common and widespread, whereas six species show range contractions of over 50%. There was a significant relationship between dietary breadth and distributional range change, with declined or declining species collecting around one-third fewer pollen types than stable species. Though there were significant compositional differences, we found no differences in the number of pollen types collected by species with differing tongue lengths. Overall, these results support the hypothesis that species with narrower dietary niches are at greater risk of decline. However, it is not clear if narrow dietary niches are a cause of declines, or if both are driven by an underlying factor such as proximity to the edge of climatic niches. Further research is needed to improve our understanding of dietary niche in bumble bees, and how it interacts with other factors to influence population trajectories of stable and at-risk species.


Subject(s)
Diet , Pollen , Animals , Asia , Bees , Europe , Michigan , North America
4.
Int J Obstet Anesth ; 39: 60-67, 2019 08.
Article in English | MEDLINE | ID: mdl-30772121

ABSTRACT

BACKGROUND: Paper-based charts remain the principal means of documenting the vital signs of hospitalised pregnant and postnatal women. However, poor chart design may contribute to both incorrect charting of data and clinical responses. We decided to identify design faults that might have an adverse clinical impact. METHODS: One hundred and twenty obstetric early warning charts and escalation protocols from consultant-led maternity units in the United Kingdom and the Channel Islands were analysed using an objective and systematic approach. We identified design errors that might impede their successful use (e.g. generate confusion regarding vital sign documentation, hamper the recognition of maternal deterioration, cause a failure of the early warning system or of any clinical response). RESULTS: We found 30% (n=36/120) of charts contained at least one design error with the potential to confuse staff, render the charts difficult to use or compromise patient safety. Amongst the most common areas were inadequate patient identification, poor use of colour, illogical weighting, poor alignment and labelling of axes, and the opportunity for staff to 'game' the escalation. CONCLUSIONS: We recommend the urgent development of an evidence-based, standardised obstetric observation chart, which integrates 'human factors' and user experience. It should have a clear layout and style, appropriate colour scheme, correct language and labelling, and the ability for vital signs to be documented accurately and quickly. It should incorporate a suitable early warning score to guide clinical management.


Subject(s)
Consultants , Vital Signs , Female , Humans , Pregnancy , United Kingdom
5.
Ecol Appl ; 28(7): 1924-1934, 2018 10.
Article in English | MEDLINE | ID: mdl-30184292

ABSTRACT

Wild bee populations have undergone declines in recent years across much of the Western world, and these declines have the potential to limit yield in pollination-dependent crops. Highbush blueberry, Vaccinium corymbosum, and tart cherry, Prunus cerasus, are spring-blooming crops that rely on the movement of pollen by bees and other insects for pollination. Wild bee populations can be increased on farmland by providing floral resources, but whether the addition of these plants translates into increased pollinator density on crop flowers has not been documented in most cropping systems. To determine the importance of providing additional floral resources for wild bee pollinator communities, we selected blueberry fields and tart cherry orchards with and without herbaceous floral enhancements in western Michigan, USA. The bee communities visiting crop flowers, enhancements and control grassy field margins were sampled over a 5-yr period. In addition, the pollen diets of the most abundant wild bee crop pollinators were quantified across Michigan to better understand their foraging niches and to identify potentially important alternative host plants. The presence of floral enhancements did not increase the abundance of wild bees on either blueberry or cherry flowers during bloom. The bee community visiting blueberry was evenly composed of short-season bees that fly only during the spring and long-season bees that fly in both spring and summer. In contrast, the bee community visiting cherry was dominated by short-season spring bees. The majority of pollen collected by the wild bee communities visiting blueberry and cherry was from spring-flowering woody plants, with limited use of the herbaceous enhancements. Enhancements attracted greater abundance and species richness of bees compared to control areas, including twice as many floral specialists. Conserving summer-flying, grassland-associated bees is an appropriate goal for pollinator conservation programs. However, herbaceous enhancements may not provide adequate resources for the wild bees that pollinate spring-flowering crops. This study demonstrates that an examination of the pollen collected by wild bees across their flight periods can identify plant species to help them persist in intensively managed landscapes.


Subject(s)
Bees/physiology , Biodiversity , Diet , Plants , Pollen , Animals , Crops, Agricultural , Feeding Behavior , Flowers , Michigan , Seasons
6.
J Econ Entomol ; 111(4): 1658-1663, 2018 08 03.
Article in English | MEDLINE | ID: mdl-29688446

ABSTRACT

Declines in the number of commercial honey bees (Apis mellifera L.) (Hymenoptera: Apidae) and some wild bee species around the world threaten fruit, nut, and vegetable production and have prompted interest in developing methods for gaining efficiencies in pollination services. One possible approach would be to deploy attractants within the target crop to increase the number of floral visits. In this study, we evaluate two new pollinator attractants, Polynate and SPLAT Bloom, for their ability to increase pollinator visitation and fruit set in apple (Malus pumila Mill.), highbush blueberry (Vaccinium sp. L.), and tart cherry (Prunus cerasus L.). Polynate is a plastic twin-tube dispenser loaded with a mixture of floral scent and Nasonov pheromone. SPLAT Bloom contains the same chemical formula as Polynate, but is applied as a 3 g wax dollop directly onto the tree or bush. The objectives of this study were to determine if Polynate and SPLAT Bloom increase the number of honey bee foragers and fruit set in apples, highbush blueberries, and tart cherries. We conducted replicated evaluations of 32 fields or orchards with and without putative attractants over three growing seasons. Both products failed to provide a measurable increase in pollinator visits or fruit set in these crops, indicating no return on investment for either product.


Subject(s)
Blueberry Plants , Malus , Prunus avium , Animals , Bees , Fruit , Pheromones , Pollination
7.
Int J Obstet Anesth ; 30: 44-51, 2017 May.
Article in English | MEDLINE | ID: mdl-28385419

ABSTRACT

BACKGROUND: Obstetric early warning systems are recommended for monitoring hospitalised pregnant and postnatal women. We decided to compare: (i) vital sign values used to define physiological normality; (ii) symptoms and signs used to escalate care; (iii) type of chart used; and (iv) presence of explicit instructions for escalating care. METHODS: One-hundred-and-twenty obstetric early warning charts and escalation protocols were obtained from consultant-led maternity units in the UK and Channel Islands. These data were extracted: values used to determine normality for each maternal vital sign; chart colour-coding; instructions following early warning system triggering; other criteria used as triggers. RESULTS: There was considerable variation in the charts, warning systems and escalation protocols. Of 120 charts, 89.2% used colour; 69.2% used colour-coded escalation systems. Forty-one (34.2%) systems required the calculation of weighted scores. Seventy-five discrete combinations of 'normal' vital sign ranges were found, the most common being: heart rate=50-99beats/min; respiratory rate=11-20breaths/min; blood pressure, systolic=100-149mmHg, diastolic ≤89mmHg; SpO2=95-100%; temperature=36.0-37.9°C; and Alert-Voice-Pain-Unresponsive assessment=Alert. Most charts (90.8%) provided instructions about who to contact following triggering, but only 41.7% gave instructions about subsequent observation frequency. CONCLUSION: The wide range of 'normal' vital sign values in different systems suggests a lack of equity in the processes for detecting deterioration and escalating care in hospitalised pregnant and postnatal women. Agreement regarding 'normal' vital sign ranges is urgently required and would assist the development of a standardised obstetric early warning system and chart.


Subject(s)
Hospital Departments/statistics & numerical data , Records , Vital Signs , Adult , Early Diagnosis , Emergency Medical Services , Female , Hospitalization , Humans , Patient Safety , Pregnancy , Records/standards , United Kingdom , Women's Health
9.
Intern Med J ; 46(6): 677-83, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26929045

ABSTRACT

BACKGROUND: Neoadjuvant systemic therapy (NAST) has become an established treatment option for women with operable breast cancer. AIM: We aimed to better understand NAST treatment patterns, barriers and facilitators in Australia and New Zealand. METHODS: We undertook a cross-sectional survey of the current clinical practice of Australian and New Zealand breast cancer specialists. Questions included referral patterns for NAST, patient selection, logistics, decision making and barriers. RESULTS: Of 207 respondents, 162 (78%) reported routinely offering NAST to selected patients with operable breast cancer (median 9% of patients offered NAST). Specialty, location, practice type, gender or years of experience did not predict for offering NAST. In all, 45 and 58% wanted to increase the number of patients who receive NAST in routine care and in clinical trials respectively. Facilitators included the multidisciplinary team meeting and access to NAST clinical trials. Specialist-reported patient barriers included: patient desire for immediate surgery (63% rated as important/very important); lack of awareness of NAST (50%); concern about progression (43%) and disinterest in downstaging (32%). Forty-three per cent of participants experienced system-related barriers to the use of NAST, including other clinicians' lack of interest (27%); lack of clinical trials (24%) and unacceptable wait for a medical oncology appointment (37%). CONCLUSION: This group of Australian and New Zealand clinicians are interested in NAST for operable breast cancer in routine care and clinical trials. Patient- and system-related barriers that prevent the optimal uptake of this treatment approach will need to be systematically addressed if NAST is to become a more common approach.


Subject(s)
Breast Neoplasms/drug therapy , Medical Oncology/methods , Neoadjuvant Therapy , Practice Patterns, Physicians' , Australia , Breast Neoplasms/surgery , Clinical Trials as Topic , Cross-Sectional Studies , Decision Making , Female , Humans , Interdisciplinary Communication , New Zealand , Patient Selection , Surgical Procedures, Operative , Surveys and Questionnaires
10.
Br J Cancer ; 111(2): 272-80, 2014 Jul 15.
Article in English | MEDLINE | ID: mdl-24901237

ABSTRACT

BACKGROUND: Ficlatuzumab, a humanised hepatocyte growth factor (HGF) IgG1κ inhibitory monoclonal antibody, was evaluated for recommended phase II dose (RP2D), safety, pharmacokinetics (PKs), antidrug antibody (ADA), pharmacodynamics (PDs) and antitumour activity as monotherapy or combined with erlotinib. METHODS: Patients with solid tumours received ficlatuzumab 2, 5, 10 or 20 mg kg(-1) intravenously every 2 weeks (q2w). Additional patients were treated at the RP2D erlotinib. RESULTS: Forty-one patients enrolled at doses ⩽20 mg kg(-1). Common adverse events (AEs) included peripheral oedema, fatigue and nausea. Three patients experienced grade ⩾3 treatment-related hyperkalaemia/hypokalaemia, diarrhoea or fatigue. Best overall response (44%) was stable disease (SD); median duration was 5.5 months (0.4-18.7 months). One patient has been on therapy with SD for >4 years. Pharmacokinetics of ficlatuzumab showed low clearance (0.17-0.26 ml h(-1) kg(-1)), a half-life of 6.8-9.4 days and dose-proportional exposure. Ficlatuzumab/erlotinib had no impact on the PK of either agent. No ADAs were detected. Ficlatuzumab increased serum HGF levels. CONCLUSIONS: Recommended phase II dose is 20 mg kg(-1) q2w for ficlatuzumab monotherapy or with erlotinib. Preliminary antitumour activity and manageable AEs were observed. Pharmacokinetics were dose-proportional and consistent with other IgG therapeutics. Ficlatuzumab was not immunogenic, and serum HGF was a potential PD marker.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Multiple Myeloma/drug therapy , Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/pharmacokinetics , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Cohort Studies , Erlotinib Hydrochloride , Female , Humans , Male , Middle Aged , Multiple Myeloma/metabolism , Multiple Myeloma/pathology , Neoplasms/metabolism , Neoplasms/pathology , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/pharmacokinetics , Quinazolines/administration & dosage , Quinazolines/adverse effects , Quinazolines/pharmacokinetics
11.
Anaesthesia ; 69(7): 687-92, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24801160

ABSTRACT

The Confidential Enquiries into Maternal Deaths in the UK have recommended obstetric early warning systems for early identification of clinical deterioration to reduce maternal morbidity and mortality. This survey explored early warning systems currently used by maternity units in the UK. An electronic questionnaire was sent to all 205 lead obstetric anaesthetists under the auspices of the Obstetric Anaesthetists' Association, generating 130 (63%) responses. All respondents reported use of an obstetric early warning system, compared with 19% in a similar survey in 2007. Respondents agreed that the six most important physiological parameters to record were respiratory rate, heart rate, temperature, systolic and diastolic blood pressure and oxygen saturation. One hundred and eighteen (91%) lead anaesthetists agreed that early warning systems helped to prevent obstetric morbidity. Staffing pressures were perceived as the greatest barrier to their use, and improved audit, education and training for healthcare professionals were identified as priority areas.


Subject(s)
Anesthesia, Obstetrical/standards , Health Care Surveys/methods , Pregnancy Complications/diagnosis , Safety Management/methods , Vital Signs/physiology , Blood Pressure , Body Temperature , Early Diagnosis , Female , Guidelines as Topic , Health Care Surveys/statistics & numerical data , Heart Rate , Humans , Oxygen/blood , Pregnancy , Respiratory Rate , Surveys and Questionnaires , United Kingdom
12.
Neotrop Entomol ; 43(3): 260-5, 2014 Jun.
Article in English | MEDLINE | ID: mdl-27193622

ABSTRACT

Considering that sensilla constitute important functional elements of sensory systems in insects, the aim of this study was to determine the type and distribution of sensilla in the antennae of Hylamorpha elegans Burmeister examined by scanning electron microscopy. Hylamorpha elegans antennae are lamellate and consist of the scape, pedicel, and flagellum. The antennal club of this beetle consists of three terminal plates: proximal, middle, and distal lamellae. Four types of sensilla were observed in the lamellae from both sexes: sensilla trichoidea, chaetica, coeloconica, and placodea. Antennal length was larger in males than in females, and significant sexual variation in the number of sensilla placodea and sensilla coeloconica was observed.


Subject(s)
Arthropod Antennae , Coleoptera/anatomy & histology , Animals , Female , Male , Microscopy, Electron, Scanning , Sensilla
13.
J Orthop Res ; 31(10): 1661-7, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23737292

ABSTRACT

The extracellular matrix (ECM) of the human intervertebral disc is rich in molecules that interact with cells through integrin-mediated attachments. Porcine nucleus pulposus (NP) cells have been shown to interact with laminin (LM) isoforms LM-111 and LM-511 through select integrins that regulate biosynthesis and cell attachment. Since human NP cells lose many phenotypic characteristics with age, attachment and interaction with the ECM may be altered. Expression of LM-binding integrins was quantified for human NP cells using flow cytometry. The cell-ECM attachment mechanism was determined by quantifying cell attachment to LM-111, LM-511, or type II collagen after functionally blocking specific integrin subunits. Human NP cells express integrins ß1, α3, and α5, with over 70% of cells positive for each subunit. Blocking subunit ß1 inhibited NP cell attachment to all substrates. Blocking subunits α1, α2, α3, and α5 simultaneously, but not individually, inhibits NP cell attachment to laminins. While integrin α6ß1 mediated porcine NP cell attachment to LM-111, we found integrins α3, α5, and ß1 instead contributed to human NP cell attachment. These findings identify integrin subunits that may mediate interactions with the ECM for human NP cells and could be used to promote cell attachment, survival, and biosynthesis in cell-based therapeutics.


Subject(s)
Extracellular Matrix Proteins/metabolism , Extracellular Matrix/metabolism , Integrins/metabolism , Intervertebral Disc Displacement/metabolism , Intervertebral Disc/metabolism , Adult , Animals , Flow Cytometry , Humans , Integrin alpha2/metabolism , Integrin alpha3/metabolism , Integrin alpha6beta1/metabolism , Integrin alphaV/metabolism , Integrin beta1/metabolism , Integrin beta3/metabolism , Intervertebral Disc/cytology , Intervertebral Disc Displacement/pathology , Laminin/metabolism , Swine
14.
Ann Oncol ; 24(7): 1828-1834, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23463624

ABSTRACT

BACKGROUND: Capecitabine and cyclophosphamide are active in patients with advanced breast cancer, have non-overlapping toxic effects and synergy pre-clinically. We explored the efficacy and toxic effect of an all-oral combination of capecitabine with cyclophosphamide versus capecitabine alone in a multicentre, randomized, phase II study. PATIENTS AND METHODS: Patients with locally advanced or metastatic breast cancer were randomized to treatment with capecitabine given continuously (666 mg/m(2) b.i.d. days 1-28) alone (C) or with oral cyclophosphamide (100 mg/m(2) days 1-14 of a 28-day cycle) (CCy) for up to six cycles. RESULTS: Eighty-two patients were randomized. There was no complete response. The proportions with partial response were 36% on C and 44% on CCy, a difference of 7.9% [95% confidence interval (CI) -13.4 to 29.1]. Significant toxic effect was uncommon: grade ≥3 diarrhoea in 4 (10%) versus 1 (3%) patients; grade ≥3 fatigue in 2 (5%) versus 5 patients (13%) and grade ≥2 hand-foot syndrome in 7 (17%) versus 11 (28%) patients receiving C versus CCy, respectively. Median progression-free survival was 3.1 months on C and 6.9 months on CCy, not significantly different statistically. There was no difference in overall survival. CONCLUSION: The difference in tumour response suggests a reasonable chance that CCy is superior to C alone.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Liver Neoplasms/drug therapy , Administration, Oral , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Breast Neoplasms/pathology , Capecitabine , Cyclophosphamide/administration & dosage , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Disease-Free Survival , Female , Fluorouracil/administration & dosage , Fluorouracil/analogs & derivatives , Humans , Liver Neoplasms/secondary , Lymphatic Metastasis , Middle Aged , Neutropenia/chemically induced , Treatment Outcome
16.
HIV Clin Trials ; 8(2): 86-97, 2007.
Article in English | MEDLINE | ID: mdl-17507324

ABSTRACT

PURPOSE: To evaluate safety and efficacy of long-term posaconazole in HIV-infected patients with azole-refractory oropharyngeal candidiasis and/or esophageal candidiasis. METHOD: In this noncomparative, open-label study, participants received oral posaconazole 400 mg twice daily (bid) for 3 months. Enrolled patients (N = 100) included 60 from a previous 1-month acute study of posaconazole and 40 posaconazole-naïve participants. Participants with a clinical response could be followed untreated for up to 1 month afterwards. Participants who relapsed during follow-up, showed improvement at the end of 3 months of treatment (EOT), or were cured but likely to benefit from further therapy could continue on posaconazole 400 mg bid for up to 12 months. RESULTS: In the modified intent-to-treat population, clinical response (cure or improvement) occurred in 85.6% (77/90) at EOT. The results were similar in the previously treated participants and the posaconazole-naïve participants, 88.1% (52/59) and 80.6% (25/31), respectively. Posaconazole was well-tolerated, showing a similar safety profile during the 3-month study period and during suppressive therapy. The most frequently reported treatment-related adverse event was vomiting (4/100, 4%) during the early follow-up period (on or before day 105) and elevated hepatic enzymes (3/51, 6%) during the long-term follow-up (after day 105). CONCLUSION: Oral posaconazole 400 mg bid demonstrated long-term safety, tolerability, and efficacy, offering a long-term, suppressive treatment option for HIV-infected participants with azole-refractory mucosal candidiasis.


Subject(s)
AIDS-Related Opportunistic Infections/drug therapy , Antifungal Agents/therapeutic use , Candidiasis/drug therapy , Esophageal Diseases/drug therapy , Pharyngeal Diseases/drug therapy , Triazoles/adverse effects , Triazoles/therapeutic use , Adult , Antifungal Agents/administration & dosage , Antifungal Agents/adverse effects , Antifungal Agents/pharmacology , Azoles/pharmacology , Azoles/therapeutic use , Candida/drug effects , Candidiasis/microbiology , Candidiasis, Oral/drug therapy , Drug Resistance, Fungal/drug effects , Enzymes/blood , Esophageal Diseases/microbiology , Female , Humans , Liver Function Tests , Male , Pharyngeal Diseases/microbiology , Treatment Outcome , Triazoles/administration & dosage , Triazoles/pharmacology , Vomiting
17.
Environ Entomol ; 36(5): 1032-9, 2007 Oct.
Article in English | MEDLINE | ID: mdl-18284725

ABSTRACT

Female obliquebanded leafrollers, Choristoneura rosaceana (Harris), collected from Oregon, Michigan, and New York were deployed in delta traps in Michigan apple orchards to compare their relative attractiveness to Michigan males of the same species. Females originating from Oregon attracted more males than females originating from New York during both generations of leafroller flight in Michigan. Also, females from Oregon attracted more males in Michigan than did "native" Michigan females during the first generation of flight. Analysis of gland extracts from the three populations revealed significantly more of each pheromone component in females originating from Oregon (approximately nine-fold more pheromone per female overall) than those from Michigan. However, there were no significant differences in the relative amounts of each pheromone component between Oregon and Michigan females. A 100:4:5:2 blend of Z11-14:OAc, E11-14:OAc, Z11-14:OH, and Z11-14:Ald was optimal for catching males in Michigan with no added or detrimental effect of Z11-14:Ald, confirming previous studies. However, 100:1 ratios of Z11-14:OAc relative to either E11-14:OAc or Z11-14:OH (also containing 2% Z11-14:Ald) captured more males in Oregon apple orchards compared with 100:4 and 100:10 ratios of Z11-14:OAc relative to either E11-14:OAc or Z11-14:OH. Addition of increasing amounts of Z11-14:Ald relative to Z11-14:OAc (range, 0-8:100) into a blend also containing 4% E11-14:OAc and 5% Z11-14:OH increased male catch in Oregon but not in Michigan. Our results suggest that pheromone blend quantity rather than blend quality may explain greater attractiveness of western compared with eastern female C. rosaceana to males in Michigan. Also, an optimized generic blend for monitoring male C. rosaceana across North America should contain Z11-14:Ald as has been previously shown, but should not exceed 4:100 ratios of both E11-14:OAc and Z11-14:OH relative to Z11-14:OAc for optimized catch of males in the western United States.


Subject(s)
Moths/physiology , Sex Attractants/physiology , Sexual Behavior, Animal/physiology , Animals , Female , Insect Control/methods , Male , Malus/parasitology , Moths/metabolism , Sex Attractants/metabolism , United States
18.
J Econ Entomol ; 99(4): 1316-20, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16937687

ABSTRACT

GF-120 is a baited formulation of the insecticide spinosad containing 1% ammonium acetate, developed for control of economically important fruit flies. The response of feral cherry fruit flies, Rhagoletis cingulata Loew, to GF-120 augmented with 0, 5, or 10% ammonium acetate was evaluated under orchard conditions. Significantly more flies were observed within 30 cm of bait droplets with 10% ammonium acetate added compared with standard bait or to a water control. These fly visits to GF-120 enhanced with 10 or 5% ammonium acetate lasted an average of 263.2 +/- 85.2 and 337.6 +/- 72.6 s, respectively, compared with 50.3 +/- 36.4 s for standard GF-120. Droplets containing additional ammonium acetate also were contacted by more flies, and more flies fed upon these droplets than on GF-120 or the water control. Furthermore, the duration of feeding on GF-120 bait enhanced with either level of additional ammonium acetate was significantly greater compared with standard GF-120 or water. Feeding events lasted between 61.5 +/- 30.7 and 73.4 +/- 21.0 s on enhanced GF-120 compared with 6.8 +/- 5.7 s on standard GF-120. Collectively, these results indicate that the interaction of feral R. cingulata with GF-120 droplets and the toxicant spinosad can be increased by addition of ammonium acetate.


Subject(s)
Acetates/pharmacology , Appetitive Behavior/drug effects , Tephritidae/drug effects , Animals , Drug Combinations , Insecticides/administration & dosage , Macrolides/administration & dosage , Prunus/parasitology
19.
Caries Res ; 38(6): 542-50, 2004.
Article in English | MEDLINE | ID: mdl-15528909

ABSTRACT

The objective of this research was to evaluate the anticaries effectiveness of a low-dose (500 ppm F, low-NaF) sodium fluoride dentifrice, a high-dose (2,800 ppm F, high-NaF) sodium fluoride dentifrice and an experimental 0.454% stabilized stannous fluoride (1,100 ppm F) with sodium hexametaphosphate (SnF2-HMP) dentifrice, each relative to a standard 1,100 ppm F sodium fluoride positive control dentifrice. Subjects (n = 955, with approximately 239 per group) with a mean age of 10.6 (approximately 9-12 years) were randomly assigned to one of four dentifrice treatments. Two calibrated examiners independently measured visual-tactile caries as DMFS that was supplemented with a radiographic examination at baseline, 12 months and 24 months for each subject. Generally similar results were independently observed by both examiners at the conclusion of the 2-year study period. Considering all subjects that attended at least 60% of the supervised brushing sessions, statistically significantly less caries was observed in the high-NaF group compared to the control group. Similarly, statistically significantly less caries was observed in the SnF2-HMP group as compared to the control group. Differences in caries increments between the low-NaF and control groups were not statistically significant. One of the examiners observed these same statistically significant differences after 1 year. In conclusion, the results of this clinical trial indicated that while no difference in caries increments was observed between the low-NaF and control groups, both the high-NaF and the SnF2-HMP groups experienced significantly fewer lesions than the control group.


Subject(s)
Cariostatic Agents/administration & dosage , Dental Caries/prevention & control , Dentifrices , Sodium Fluoride/administration & dosage , Tin Fluorides/administration & dosage , Child , DMF Index , Dentifrices/chemistry , Double-Blind Method , Drug Combinations , Female , Humans , Male , Observer Variation , Phosphates/administration & dosage , Reproducibility of Results , Sensitivity and Specificity
20.
Caries Res ; 38(4): 350-6, 2004.
Article in English | MEDLINE | ID: mdl-15181334

ABSTRACT

The objective of this study was to determine the ability of several techniques to detect natural secondary caries adjacent to proximal class II amalgam restorations. Two sites were selected and marked on each of 50 human extracted posterior teeth. Three examiners visually characterized each site independently for signs of demineralization (VI), ditching presence (VD), and color change, and utilized light-induced fluorescence (QLF), and infrared laser fluorescence (LF) techniques. The teeth were sectioned through the selected sites, and the severity of each lesion was determined by confocal laser scanning microscopy (CLSM) as the 'gold standard'. Agreement among examiners was assessed using weighted kappa statistics and showed fair to moderate correlation with all techniques. Sensitivity, specificity, positive predictive value (PPV), negative predictive value and accuracy were determined by utilizing three arbitrary CLSM thresholds. Higher sensitivity was indicated by the QLF and LF than by VI. For PPV and accuracy, QLF and LF showed values higher or similar to VI. Low sensitivity was found for VD. The results obtained in this study suggest that LF and QLF may improve the ability to detect early secondary caries around amalgam restorations.


Subject(s)
Dental Caries Activity Tests , Dental Caries/diagnosis , Dental Amalgam , Dental Restoration, Permanent , Fluorescence , Humans , Lasers , Light , Microscopy, Confocal , Observer Variation , ROC Curve , Recurrence , Reproducibility of Results , Sensitivity and Specificity , Tooth Discoloration/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...